<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a prospective, open clinical trial, we studied long-term effects of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CsA) on the optic nerve and <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> in 14 Behçet's disease patients </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were treated with CsA and <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> for a mean period of 42 months, with a range of 36 to 52 months </plain></SENT>
<SENT sid="2" pm="."><plain>They received an initial CsA dosage of 7 mg/kg/day for three days, followed by 5 mg/kg/day, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> 1 mg/kg/day for three to five days, tapered to 0.4 mg/kg/day </plain></SENT>
<SENT sid="3" pm="."><plain>CsA was tapered when clinical response was noted </plain></SENT>
<SENT sid="4" pm="."><plain>Improvement occurred in visual acuity and <z:hpo ids='HP_0001123'>visual field defects</z:hpo> secondary to <z:e sem="disease" ids="C0162293" disease_type="Disease or Syndrome" abbrv="">papillitis</z:e>, <z:hpo ids='HP_0100653'>optic neuritis</z:hpo>, macular <z:e sem="disease" ids="C0154874" disease_type="Disease or Syndrome" abbrv="">neuroretinitis</z:e>, and <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:mp ids='MP_0010140'>phlebitis</z:mp>, but not with <z:hpo ids='HP_0008030'>retinal arteritis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Despite a 12/14 (85%) exacerbation rate, no permanent liver or renal lab tests abnormalities were noted </plain></SENT>
<SENT sid="6" pm="."><plain>Intermittent, low-dose CsA therapy may be considered in treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="46" ids="15035">retinal</z:chebi> and optic nerve <z:hpo ids='HP_0002633'>vasculitis</z:hpo> assisted with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>